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ABSTRACT  
Cerebral ischemia and excitotoxic injury induce transient or permanent 
bioenergetic failure, and may result in neuronal apoptosis or necrosis. We have 
previously shown that ATP depletion and activation of AMP-activated protein kinase 
(AMPK) during excitotoxic injury induces neuronal apoptosis by transcription of the pro-
apoptotic BH3 only protein, Bim. AMPK, however, also exerts pro-survival functions in 
neurons. The molecular switches that determine these differential outcomes are not well 
understood. Using an approach combining biochemistry, single cell imaging and 
computational modeling, we here demonstrate that excitotoxic injury activated the bim 
promoter in a FOXO3-dependent manner. The activation of AMPK reduced AKT 
activation, and led to dephosphorylation and nuclear translocation of FOXO3. 
Subsequent mutation studies indicated that bim gene activation during excitotoxic injury 
required direct FOXO3 phosphorylation by AMPK in the nucleus as a second activation 
step. Inhibition of this phosphorylation prevented Bim expression and protected neurons 
against excitotoxic and oxygen/glucose deprivation-induced injury. Systems analysis and 
computational modeling revealed that these two activation steps defined a coherent feed-
forward loop; a network motif capable of filtering any effects of short-term AMPK 
activation on bim gene induction. This may prevent unwanted AMPK-mediated Bim 
expression and apoptosis during transient or physiological bioenergetic stress. 
KEYWORDS: Excitotoxicity; Energy depletion; AMPK; BH3-only protein BIM; 
FOXO3; Computational Modeling, Network motifs. 
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Abbreviations: AKT-CA, constitutively active mutant of AKT; AMPK-CA, 
constitutively active mutant of AMPK. CC, Compound C; CFL, coherent feed-forward 
loop; CGNs, cerebellar granule neurons; 6xDBE FOXO3 promoter, reporter luciferase 
plasmid with six copies of the FOXO family protein-binding element; DN-FOXO3, 
dominant negative FOXO3; FOXO3-6A, construct with FOXO3 sequence mutated at the 
AMPK phosphorylation sites; FOXO3-nuclear, construct with FOXO3 sequence mutated 
at the AKT phosphorylation sites; GLY, Glycine; GLUT, Glutamate; OGD, 
Oxygen/glucose deprivation; PI, Propridium iodide; RLUs: Relative luciferase counts; 
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INTRODUCTION  
Excitotoxicity has been implicated in the pathogenesis of cerebral ischemia and 
several neurodegenerative disorders
1-3
, and results from abnormal levels of the excitatory 
neurotransmitter glutamate in the synaptic cleft
4
. The extent of ATP depletion during 
excitotoxic injury critically determines neuronal outcome
7
. Neurons that fail to restore 
their ATP levels undergo rapid excitotoxic necrosis
7
. However, many of the neurons that 
initially overcome the energetic crisis and recover their ATP levels nevertheless undergo 
a delayed apoptotic death
8
. ATP depletion activates the AMP-activated protein kinase 
(AMPK) which adapts the cellular response to bioenergetic stress
9
. AMPK switches off 
anabolic pathways, preventing ATP consumption, and switches on catabolic pathways, 
increasing glucose uptake and ATP production
10
. AMPK-dependent plasma membrane 
translocation of the glucose transporter (GLUT) 3, and subsequent glucose uptake 
mediate tolerance of neurons to excitotoxic or ischemic injury
11,12
. In contrast to these 
cytoprotective mechanisms, however, prolonged AMPK activation has also been shown 
to contribute to ischemic injury and excitotoxicity
9,13,14
. We recently demonstrated that 
prolonged activation of AMPK mediates excitotoxic apoptosis by inducing the expression 
of the pro-apoptotic Bcl-2 family protein Bim
13
. However the mechanisms that AMPK 
utilizes to switch on the transcriptional activation of bim during excitotoxic apoptosis 
remain unknown. Here, we describe the signaling pathways that couple AMPK activation 
to bim gene expression during excitotoxic apoptosis, and provide a mathematical frame-
work that explains cell fate decision making during AMPK activation. 
 5 
RESULTS 
Bim induction during excitotoxic apoptosis requires AP-1 and FOXO3 
We have previously shown that brief stimulation of NMDA receptors in cortical neurons 
or cerebellar granule neurons (CGNs) induces a bim-dependent, delayed excitotoxic cell 
death characteristic of caspase-independent apoptosis
11,13,15
. Western blot (Fig. 1A) and 
qPCR analysis confirmed that CGNs exposed to glutamate/glycine (100/10 µM) showed 
elevated Bim levels. Excitotoxic injury was significantly reduced in CGNs deficient in 
bim (Fig. 1B). 
We next addressed the signaling pathways involved in bim activation during 
excitotoxic injury. Excellent candidates are the FOXO3 and AP-1 transcription factors 
which have been implicated in Bim expression during neuronal apoptosis
13,16-18
. We 
transfected CGNs with a reporter construct bearing the wild type bim promoter sequence, 
or bim promoter constructs harboring mutations in the FOXO3 or AP-1 binding sites. 
Luciferase activity was significantly increased in glutamate treated neurons expressing 
the wild type bim promoter. However, this effect was abrogated by either bim promoter 
mutation (Fig.1C), indicating that FOXO3 and AP-1 binding sites were necessary for bim 
promoter activation. 
 
AMPK-dependent down-regulation of the mTOR/AKT pathway during 
excitotoxicity 
Previously we demonstrated that pAMPK activated JNKs, with JNK activation 
contributing to bim expression and apoptosis
13
. We therefore next focused on exploring 
the role of FOXO3 activation in bim gene induction, and its control by AMPK. Firstly, 
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we analyzed AMPK activation during excitotoxicity by Western blot analysis of 
pAMPKα (Thr172) levels. AMPK activation was evident 10 min after glutamate 
exposure, and recovered to baseline levels after 120 min (Fig. 2A).  
The mTOR kinase complex (mTORC) is negatively regulated by AMPK
19
. To 
address the regulation of mTORC during excitotoxicity, we monitored phospho-mTOR 
(Ser2448) levels (Fig. 2B). Glutamate treatment decreased p-mTOR levels 10 min after 
exposure, coinciding with the peak of AMPK activation. Notably, p-mTOR levels were 
persistently down-regulated in response to glutamate. mTORC2 has been described as an 
important activator of the pro-survival kinase AKT
20
. We detected an early decrease in 
pAKT (Ser473) levels in response to glutamate (Fig. 2C). In contrast to p-mTOR, 
however, pAKT levels partially recovered 2-8 h after glutamate exposure with complete 
recovery after 16/24 h. The inactivation of AKT enables FOXO3-dependent gene 
transcription by preventing the cytosolic translocation of FOXO3
21
. Western blot analysis 
of phospho-FOXO3 (Thr32) levels showed a significant decrease 2-4 h after glutamate 
exposure (Fig. 2D). 
To demonstrate that AMPK activation was responsible for the decrease in pAKT 
levels during excitotoxic injury, we depleted AMPK levels with vectors expressing a 
siRNA targeting AMPK-α1/α2, or a control sequence13 (Supplementary Fig. 1). CGNs 
with depleted AMPK levels presented significantly higher levels of phospho-AKT 
(Ser473) compared to control transfected neurons (Fig. 2E). This result was confirmed 
using the pharmacological inhibitor of AMPK, compound C (CC). CGNs pretreated with 
CC (10 µM) 45 min prior to glutamate exposure presented with 69.5 ± 19.5% higher 
phospho-AKT (Ser473) levels 30 minutes after glutamate treatment, compared to those 
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pre-treated with vehicle (data not shown). AMPK-α1/α2 depletion also increased 
phospho-FOXO3 (Thr32) levels in neurons exposed to glutamate (Fig. 2E). Confirming 
the down-regulation of FOXO3 phosphorylation by AMPK, transfection of CGNs with a 
constitutively active mutant of AMPK (AMPK-CA) resulted in a decrease in phospho-
FOXO3 (Thr32) levels and an increase in Bim expression (Supplementary Fig. 2A,B). 
Finally, to demonstrate that FOXO3 dephosphorylation was a consequence of AKT 
down-regulation, we transfected CGNs with a constitutive active mutant of AKT (AKT-
CA). The expression of AKT-CA prevented the decrease in phospho-FOXO3 (Thr32) 
levels 2 and 4 h after glutamate exposure (Fig. 2F). 
 
AMPK activation during excitotoxicity induces FOXO3 nuclear translocation 
We next analyzed whether the nuclear presence of FOXO3 was also increased in 
response to glutamate. CGNs were transfected with a FOXO3-GFP plasmid and exposed 
to either glutamate/glycine (100/10 µM) or experimental buffer. Confocal images of 
single neurons were taken for FOXO3-GFP, Hoechst 33258 and Propidium iodide (PI). 
Quantification of the GFP fluorescence intensity inside and outside the nucleus allowed 
the calculation of a nuclear/cytoplasmic FOXO3-GFP ratio. In cells exposed to 
glutamate, 29.3 ± 8.3% of neurons showed a sudden and permanent increase in this ratio, 
occurring with a delay that varied between 1 and 5 h after glutamate exposure (mean 
delay of 3 h 28 min ± 33 min) (Fig. 3A,B). Of note, all neurons that exhibited this sudden 
and permanent increase underwent nuclear shrinkage and cell death 7-12 h after 
glutamate exposure (mean time point 9 h 14 min ± 56min), as indicated by the loss of the 
GFP fluorescence signal and an increase in PI fluorescence. The remaining neurons 
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which survived (62.8 ± 2.1% of the total population) did not show any change in their 
nuclear/cytoplasmic ratio, or showed a transient increase that recovered to baseline levels 
(mean duration of ratio increase 1 h 2min ± 7min) (Supplementary Fig. 3A,B). Cells 
exposed to experimental buffer only did not show any alterations in the 
nuclear/cytoplasmic FOXO-GFP ratio (Supplementary Fig. 3C). 
We investigated whether AMPK activation alone was sufficient to induce FOXO3 
nuclear translocation. Expression of the AMPK-CA construct significantly increased the 
percentage of neurons showing FOXO3-GFP nuclear presence when compared to cells 
transfected with a control vector (Supplementary Fig. 2C). 
We next tested whether the nuclear translocation of FOXO3-GFP during 
excitotoxic injury was prevented either by expression of AKT-CA, or by inhibition of 
AMPK. We compared the percentage of cells exhibiting nuclear, cytoplasmic, or 
cytoplasmic and nuclear presence of FOXO3-GFP 3.5 h after glutamate or vehicle 
exposure. Glutamate exposure significantly increased the percentage of neurons with 
nuclear FOXO3-GFP compared to control neurons, and decreased the percentage of 
neurons with cytoplasmic FOXO3-GFP (Fig. 3C,D). Both effects were abrogated by 
AKT-CA expression (Fig. 3C) or by pre-treatment with CC (10 µM) (Fig. 3D). These 
results were confirmed with immunofluorescence experiments on neurons transfected 
with AMPK siRNA (Fig. 3E,F). These data demonstrated that excitotoxic injury induces 
FOXO3 nuclear translocation in an AMPK- and AKT-dependent manner. 
 
FOXO3 nuclear translocation is not sufficient for bim expression and cell death 
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In addition to FOXO3 nuclear translocation, further posttranslational modifications may 
be necessary to stimulate its transcriptional activity
17,22
. This hypothesis was tested by co-
expressing the bim promoter plasmid with a FOXO3 construct, mutated at the AKT 
phosphorylation sites and therefore permanently localized to the nucleus (‘FOXO3-
nuclear’21). Glutamate/glycine (100/10 µM) exposure significantly increased luciferase 
activity in CGNs expressing ‘FOXO3-nuclear’ (Supplementary Fig. 4A), suggesting that 
FOXO3 required further posttranslational modifications to increase its binding to the bim 
promoter. Additional single-cell experiments implicated AMPK in mediating these 
events. Neurons transfected with FOXO3-GFP were exposed to glutamate, and two hours 
later treated with CC (10 µM). We hypothesized that this treatment paradigm would 
avoid AMPK inhibition during or shortly after glutamate exposure, allowing FOXO3 
nuclear translocation, but inhibiting AMPK subsequent to this. Indeed, late addition of 
CC did not prevent FOXO3-GFP nuclear translocation. However, all neurons which 
displayed a permanent FOXO3 nuclear translocation failed to undergo subsequent 
nuclear shrinkage and cell death (Fig. 4A,B), and remained viable until termination of the 
experiments. 
To corroborate these single cell experiments we analyzed Bim and FOXO3 
expression and localization by Western blotting in CGNs treated with CC 2 h after 
glutamate exposure. CC treated neurons expressed lower levels of Bim, without a 
decrease in FOXO3 nuclear translocation (Fig. 4C,D). Glutamate induced cell death was 
also significantly impaired in this setting (Fig. 4E). Taken together this data suggests that 
AMPK may have a further essential role in bim activation that extends beyond inducing 
FOXO3 translocation, and that requires prolonged AMPK activity. 
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We also investigated FOXO3 translocation and Bim expression during varied 
durations of pharmacologically-induced AMPK activity. We found that whilst CGNs 
subjected to continuous AICAR treatment (2.5 mM) showed increased Bim expression, 
no significant Bim induction occurred with transient addition of AICAR to the cultures 
for 1 h despite FOXO3 nuclear translocation in both treatment paradigms. Increased 
nuclear localization of pAMPK was also observed after continuous, but not transient, 
AICAR treatment (Fig. 4F), confirming that prolonged AMPK activation is required for 
Bim expression, and suggesting that nuclear pAMPK may mediate this Bim expression. 
 
FOXO3 activation by AMPK is a coherent feed-forward network motif that can act 
as a suppressor of transient stress signals  
To understand the regulatory role of AMPK in FOXO3 activation and Bim expression 
from a systems point of view, we employed computational modeling. Initially, we 
modeled (by ordinary differential equations) a one-step FOXO3 activation where 
pAMPK-mediated Akt inhibition lead to FOXO3 dephosphorylation (FOXO3dephos) and 
activated FOXO3 for Bim expression (Fig. 5A, denoted by (1)). This ‘linear’ pathway 
predicted a similar FOXO3 activation, and therefore Bim expression, following both 
short-term and long-term periods of AMPK activity (Fig. 5B). However, this linear model 
neither explained our results that the duration of AMPK activation may determine 
whether Bim is expressed or not (Fig. 4F), nor did it support previous findings that short-
term pAMPK activation was neuroprotective
11,23
. We therefore assumed that an 
additional regulation step was required to prevent Bim expression following short-term 
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AMPK activation, while maintaining robust Bim expression following prolonged AMPK 
activation. 
We incorporated into our model a second activation step of FOXO3dephos by 
pAMPK (‘FOXO3ampk’) (Fig. 5A, dashed line denoted by (2)). In this model, Bim 
induction was suppressed for short-term pAMPK activity (Fig. 5C, 40 min), as the 
pAMPK signal (second activation step) was no longer active by the time the signal of the 
first activation step had induced FOXO3 dephosphorylation. Prolonged pAMPK 
activation, however, outlasted the delay of the first step and led to a pronounced increase 
in Bim expression (Fig. 5C, 100 min). This gave a qualitatively good explanation of our 
findings in Fig. 4F, where long term AMPK activation led to significant Bim expression, 
while short term activation did not. The inclusion of a second FOXO3 activation step by 
pAMPK resulted in a network motif known as a coherent feed-forward loop (CFL).  
 
AMPK induces bim expression by direct FOXO3 phosphorylation 
AMPK has been shown to regulate the DNA-binding of transcription factors by direct 
phosphorylation
10,24,25
. Interestingly, in non-neuronal cells, AMPK has been shown to 
specifically activate FOXO3 by phosphorylation
24
. To validate the modeling results we 
tested if AMPK-phosphorylation of FOXO3 was required for Bim expression. We co-
expressed a FOXO3 construct (FOXO3-6A) which is mutated at the six residues (Thr179, 
Ser399, Ser413, Ser439, Ser555, and Ser588) phosphorylated by AMPK, alongside the 
bim promoter reporter plasmid. As expected, CGNs co-transfected with FOXO3 wild-
type (wt) and treated with glutamate showed a significant increase in luciferase activity 
compared to control neurons. However, in neurons co-transfected with the FOXO3-6A 
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mutant, this effect was abrogated (Fig. 6A upper panel). These results were also 
confirmed by Western-Blot analysis of Bim protein levels (Fig. 6A lower panel). 
Next we tested whether FOXO3 translocation during excitotoxicity also required 
FOXO3 phosphorylation by AMPK. CGNs were transfected with FOXO3-6A or FOXO3 
wild type constructs and then exposed to glutamate or experimental buffer. Three hours 
after exposure cultures were subjected to sub-cellular fractionation. Glutamate treatment 
induced a similar increase in FOXO3 wt and FOXO3-6A nuclear levels when compared 
to control neurons (Fig. 6B). A similar decrease was observed in cytosolic FOXO3 wt 
and FOXO3-6A levels (Flag M2-tag), suggesting that FOXO3 phosphorylation by 
AMPK did not affect FOXO3 translocation. We also observed that pAMPKα (Thr172) 
levels were increased in the nucleus and decreased in the cytosol after glutamate 
treatment (Fig. 6B), suggesting the nuclear translocation of both pAMPK and FOXO3 
during excitotoxicity. We next directly tested whether the phosphorylation state of 
FOXO3 in the nucleus depended on AMPK activity. CGNs transfected with the 
‘FOXO3-nuclear’ mutant were pre-treated with CC (10 µM) and later exposed to 
glutamate. Four hours later, we detected elevated levels of ‘FOXO3-nuclear’ serine 
phosphorylation in neurons exposed to glutamate when compared to controls. This effect 
was abrogated in neurons pre-treated with CC (Fig. 6C). 
The above results showed that FOXO3 phosphorylation by AMPK increased bim 
promoter activation during excitotoxic injury. This phosphorylation was specific to the 
bim promoter, since FOXO3-6A expression did not affect the activation of a chimeric 
promoter bearing six canonical FOXO binding elements (TTGTTTAC box) not present 
in the bim promoter (Supplementary Fig. 4B). We next tested if inhibition of FOXO3 
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phosphorylation by AMPK could facilitate the activation of alternative FOXO3 targets, 
such as the promoter of the stress tolerance gene MnSOD
22
. A FOXO3 wt or a FOXO3-
6A construct were co-expressed with a luciferase reporter plasmid containing the MnSOD 
promoter sequence (pSOD-luc) in CGNs. Glutamate exposure increased luciferase 
activity in control neurons transfected with FOXO3 wt (Fig. 6D). However, FOXO3-6A 
expression increased luciferase activity in neurons exposed to either experimental buffer 
or glutamate. This effect was abrogated by mutation of the FOXO3 binding sites in the 
MnSOD promoter (pSOD-luc-mut) (Fig. 6D). 
 
FOXO3 activation by AMPK is required for cell death 
Next we analyzed whether inhibition of FOXO3 phosphorylation by AMPK decreased 
neuronal injury during excitotoxicity (Fig. 7A). We co-transfected CGNs with a GFP-
expressing plasmid and either the FOXO3 wt, dominant negative FOXO3 (DN-FOXO3), 
or FOXO3-6A expression plasmid. Cell death was determined by evaluating the 
percentage of PI
+ 
and GFP
+
 cells before and 16 h after glutamate/glycine (100/10 µM) 
exposure. As
 
shown in Fig. 7A, FOXO3-wt transfected neurons treated with glutamate 
showed significantly higher levels of cell death than neurons exposed to vehicle. 
However, cell death was negligible in cells transfected with DN-FOXO3 or FOXO3-6A. 
To explore the possible relevance of FOXO3 regulation by AMPK in ischemic 
neuronal death, we subjected primary mouse cortical neurons to oxygen/glucose 
deprivation (OGD) induced neuronal injury. Neurons were co-transfected with a GFP-
expression vector and
 
either DN-FOXO3, or FOXO3-6A expression constructs. Cultures 
were subjected to OGD for 30 min in a hypoxia chamber, and subsequently returned to 
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normoxic/normoglycemic conditions for 24 h. Cell death was determined by evaluating 
the percentage of pyknotic nuclei in the GFP
+
 cells. As shown in Fig. 7B, transfection 
with FOXO3-6A led to significantly lower levels of cell death when compared to cells 
co-transfected with a control plasmid, an effect that was comparable to the effect of DN-
FOXO3. 
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DISCUSSION  
The present study describes the pro-apoptotic activity of the energy sensor AMPK 
during excitotoxic injury. While AMPK activation has been associated with cell 
survival
11,23,26
, it is now evident that it is also involved in long-term cell fate decisions. 
AMPK activation has been shown to activate apoptosis in different cell types
27,28
, 
including neurons
9,13
, and this apoptosis occurs after prolonged periods of AMPK 
activation
27,28
. AMPK has also been shown to mediate ischemic neuronal death in vivo
14
. 
As apoptosis is a terminal cellular decision, the signaling pathways controlling the pro-
apoptotic activities of AMPK require a complex regulation. We here demonstrate that the 
combined activation of AP-1 and FOXO3 transcription factors by AMPK is required for 
the transcriptional activation of the pro-apoptotic bim gene. Indeed, bim activation and 
cell death induction required both AMPK-dependent FOXO3 nuclear translocation and 
direct FOXO3 phosphorylation by AMPK. Systems analysis and computational modeling 
showed that this two-step activation of FOXO3 provides a means for filtering out effects 
of short-term AMPK activation on bim induction, while providing robust bim activation 
following prolonged AMPK activity. 
Previous work from our group has demonstrated that AMPK mediates cell death 
by expression of the pro-apoptotic BH3-only proteins Bim and, in some cell types, 
Bmf
13,29
.  Bim promoter mutation of either the FOXO3 or the AP-1 binding site prevented 
bim activation in neurons during excitotoxicity. We demonstrate that in addition to the 
engagement of multiple transcription factors, individual transcription factors may also be 
subject to additional posttranslational control steps in order to efficiently activate bim 
transcription. We observed that AMPK transiently inhibited AKT signaling during 
 16 
excitotoxicity, and that AKT-mediated FOXO3 dephosphorylation was a key step that 
allowed for the nuclear translocation of FOXO3
21
. This translocation was permanent in 
neurons which underwent apoptosis, and was transient or did not occur in surviving cells. 
Specific mechanisms must therefore exist to restore pAKT/pFOXO3 levels in surviving 
neurons. Survival responses during excitotoxicity have been associated with enhanced 
neuronal glucose uptake and ATP availability, as well as with growth factor signalling
9,12
, 
suggesting that these factors could restore pAKT/pFOXO3 levels. The persistent mTOR 
dephosphorylation after glutamate exposure suggests the involvement in this process of 
other AKT regulators besides mTOR. Given the central role of AKT in several cell 
survival pathways such as PI3K and GSK-3 signaling30, the regulation of AKT 
independently from mTOR and AMPK pathways is not surprising and may involve 
phosphatases such as PP2A or PTEN
31,32
. 
The AKT-dependent nuclear translocation of FOXO3, however, was not the sole 
determinant of FOXO3-dependent bim gene expression. Both biochemical and single-cell 
imaging experiments, as well as experiments using FOXO3-6A, demonstrated that bim 
activation and cell death additionally required FOXO3 phosphorylation by AMPK. In 
contrast, the transcription of the MnSOD promoter was stimulated by FOXO3-6A 
expression alone. This finding suggested that direct phosphorylation by AMPK could 
guide FOXO3 towards its binding to the bim promoter instead of towards others targets 
such as the MnSOD promoter. 
The two-step activation of FOXO3 by AMPK is a CFL network motif. Well 
established in systems biology, and overrepresented in pathways of gene regulation, 
CFLs are known to induce gene expression upon sustained, but not transient signals
33,34
. 
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Indeed, our identified CFL enables the filtering of transient AMPK impulses so that 
shorter periods of AMPK activity did not lead to Bim induction and allow pAMPK to 
exert its pro-survival effects
11
. This filtering is achieved by the delay required for the 
AKT-mediated FOXO3 dephosphorylation in the first activation step. The period of 
AMPK activity must outlast this delay to activate FOXO3 in the second activation step. 
Increased survival signaling, through AKT activation, would prolong the delay of the first 
activation step, requiring a longer period of AMPK activity to induce Bim expression. 
This idea is supported by evidence showing a reduction in apoptosis following 
stimulation of AKT
35
. Consequently, the CFL of FOXO3 activation may regulate Bim 
expression based on both stress duration and the extent of pro-survival signaling. 
Previously we demonstrated the involvement of JNK in Bim expression and the 
nuclear translocation of C-JUN induced by AMPK during excitotoxicity
13
. Neurons have 
high levels of constitutive JNK1 activity
36
 so it remains to be shown whether any surplus 
activation of JNK by AMPK contributes to bim gene induction during excitotoxic 
apoptosis. Such a potential third activation step by AMPK cannot be excluded, and may 
integrate other stress-related signals to form a more complex cascade of CFLs. Oxidative 
stress, for example, may activate the JNK/AP-1 pathway
36
. Similarly, we cannot exclude 
a role of other transcription factors, such as Myb
18
, in bim activation. Likewise, the 
FOXO family of transcription factors may be subject to other posttranslational 
modifications such as JNK phosphorylation or SIRT1 de-acetylation
22,37
. 
AMPK has previously been shown to control the DNA-binding of different 
transcription factors or co-factors by phosphorylation
10,24,25
. AMPK phosphorylation of 
FOXO3 was not required for its nuclear translocation (see also 
24
). However, it is possible 
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that FOXO3 dephosphorylation and its subsequent nuclear translocation is a requirement 
for subsequent posttranslational modifications (i.e. FOXO3 phosphorylation by 
AMPK)
17
. Indeed, this is a necessary condition for the functioning of the proposed CFL. 
We provided evidence of nuclear effects of AMPK on FOXO3 with Bim induction only 
detected after sustained AMPK activation and nuclear presence of pAMPKα. Shorter 
periods of AMPK activity did not lead to AMPK translocation or Bim expression, 
although FOXO3 nuclear translocation was maintained in both scenarios. This evidence 
suggested that interaction of FOXO3 and AMPK in the nucleus could be a requirement 
for bim promoter activation and apoptosis. Interestingly, neuronal apoptosis was recently 
described in a model of Huntington’s disease as dependent on nuclear accumulation of 
AMPK-138. 
In conclusion, our data suggest that FOXO3 activation represents a key step 
during bim-mediated excitotoxic neuronal death. The complex interplay between cellular 
bioenergetics, AMPK activation, and mTOR/AKT/FOXO3 signaling provides a 
molecular framework for cell fate decision making, preventing unwanted apoptosis 
activation during physiological AMPK activation or during conditions of mild bio-
energetic stress. 
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MATERIALS AND METHODS 
 
Materials. Fetal calf serum and minimal essential medium were obtained from Invitrogen 
(Bio Sciences, Dublin, Ireland). Glutamate, glycine, Hoechst 33258 and Propidium 
iodide (PI) were from Sigma-Aldrich (Arklow, Ireland). AICAR was from Cell Signaling 
(Isis Ltd., Bray, Ireland). Compound C (CC) was obtained from Calbiochem (Merck 
Biosciences, Nottingham, UK). 
 
Preparation of primary cerebellar granular neurons (CGNs). Both mouse (C57BL) or rat 
(Sprague-Dawley) cerebella were isolated from postnatal day 7 pups. CGN cultures were 
obtained as described previously
7
. Cells were plated on poly-Lysine-coated glass 
coverslips, glass Willco dishes, 6-well plates, and 24-well plates at 1 x 10
6
 cells per 
milliliter, and maintained at 37°C in a humidified atmosphere of 5% CO2 / 95% air. 
Experiments were performed after 8-10 days in vitro. All animal work was performed 
with ethics approval from the RCSI and under licenses granted to the authors by the Irish 
Department of Health and Children. 
 
Plasmids, siRNA and transfection. The FOXO3-GFP plasmid in an EGFP-N1 vector 
backbone was kindly provided by M.P Smidt (University Medical Center, Utrecht, The 
Netherlands). The AMPK-CA construct is the truncated version of AMPK1 after 
residue 312 and includes a Myc-tag and was a kind gift from David Carling (Imperial 
College London, London, UK). The AKT-CA construct expresses the myristoylated 
AKT-1 sequence and was kindly provided by S. Pons (Biomedicine Institute, CSIC, 
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Barcelona, Spain). The Firefly luciferase reporter plasmid containing 0.8 kB of the bim 
promoter sequence along with similar constructs with mutated FOXO3 or AP-1 binding 
sites were kindly provided by Eric Lam (Imperial College London, London, UK). The 
pECE-FOXO3-TM (termed here ‘FOXO3-nuclear’), a construct mutated at the three sites 
(T32A/S253A/S315A) of AKT phosphorylation and permanently located in the nucleus, 
was kindly provided by M.E. Greenberg (Harvard Medical School, Boston, USA). The 
pECE-FOXO3-M2-flag and pECE-FOXO3-6A-M2-flag (sextuple mutant 
T179A/S339A/S413A/S555A/S588A/S626A at the sites for AMPK phosphorylation) 
were kind gifts from A. Brunet (Harvard Medical School, Boston, USA). The pmax-GFP 
construct was obtained from LONZA (Basel, Switzerland). The pRL-TK (TK-Renilla 
luciferase), the p6xDBE-luc (reporter luciferase plasmid with six copies of the FOXO 
family protein-binding element), and the reporter plasmids containing the MnSOD 
promoter sequence (pSOD-luc) along with a similar construct with mutated FOXO3 
binding sites (pSOD-luc-mut) were a kind gift from B.M. Burgering (University Medical 
Center, Utrecht, The Netherlands). The dominant negative construct of FOXO3 (DN-
FOXO3) expresses the DNA-binding domain (amino acids 141-268) of pECE-FOXO3-
TM, and was kindly provided by I. Torres-Aleman (Cajal Institute, CSIC, Madrid, 
Spain). siRNA targeting AMPK-α1/α2 (pFIV-AMPK-siRNA) and the control sequence 
(pFIV-Control-siRNA) were previously described
11
. CGNs were transfected using 
calcium phosphate as previously described
11
, the transfection reagent Neurofect from 
Genlantis (AMS Biotechnology, Milton, UK), or an electroporation kit (LONZA) as per 
manufacturer’s instructions. 
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Live cell microscopy. CGNs on glass Willco dishes (WillCo Wells B.V., Amsterdam, The 
Netherlands) were transfected with a FOXO3-GFP construct. 48 h later cells were treated 
for 30 min with glutamate and glycine (100 µM and 10 µM) in experimental buffer (120 
mM NaCl, 3.5 mM KCl, 0.4 mM KH2PO4, 20 mM HEPES, 5 mM NaHCO3, 1.2 mM 
Na2SO4, 1.2 mM CaCl2, 1.2 mM MgCl2 and 15 mM glucose; pH 7.4). Control CGNs 
were treated with experimental buffer only. Next, CGNs were stained with Hoechst 
33258 and PI at a final concentration of 0.1 μg/ml. Following treatment the pre-
conditioned medium, supplemented with HEPES (final concentration 20 mM), was 
replaced onto the cells and the dish was placed on the stage of a confocal microscope 
equipped with a 63x 1.4 NA oil immersion objective and a thermostatically regulated 
chamber at 37°C (LSM 710, Carl Zeiss, Germany). A thin layer of mineral oil (1.5 ml) 
was added onto the medium to prevent evaporation. GFP was excited at 488 nm with an 
Argon laser (AOTF set to 0.5%) and the emission collected in the range of 493-552 nm. 
Hoechst 33258 was excited at 405 nm (1% transmission, ND filter and AOTF) and the 
emission detected in the range of 410 to 480 nm. For the detection of plasma membrane 
permeabilization PI was excited at 543 nm (AOTF 1.5% transmission) and fluorescence 
emission was detected above 570 nm. Images were captured at 5 min intervals at 1.5 µm 
optical slice thickness. The resulting images were processed using MetaMorph 7.5 
software (Molecular Devices, Wokingham, UK). The GFP average intensity fluorescence 
signal was quantified at the nucleus and cytoplasm to determine the nuclear/cytoplasmic 
FOXO3-GFP ratio. At least 33 single cell experiments were analyzed for cells treated 
with glutamate, and 6 for those treated with experimental buffer. For quantification of 
FOXO3 nuclear translocation in neuronal populations, CGNs were plated on 24 well 
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plates. 3.5 h after glutamate/experimental buffer exposure, neurons were incubated for 30 
min with Hoechst 33258 (final concentration 1 μg/ml) and PI (final concentration 0.2 
µg/ml). For each group, 80-90 cells were analyzed in three independent experiments 
using an Eclipse TE 2000s inverted microscope (Nikon, Amstelveen, The Netherlands) 
and a 40x 0.6NA objective. Images of GFP, PI and Hoechst signals of single neurons 
were taken and processed with Image J software (NIH, Bethesda, USA) to determine the 
nuclear/cytoplasmic FOXO3-GFP ratio. Neurons were scored as follows: FOXO3-GFP 
cytoplasmic (ratio <0.9), FOXO3-GFP nuclear (ratio >1.1), FOXO3-GFP 
cytoplasmic/nuclear (0.9 < ratio < 1.1). 
 
Western blotting and Immunoprecipitation. Western blotting was performed as 
described
11
. Neurons were lysed with PIK buffer (1% NP-40, 150 mM NaCl, 20 mM 
Tris, pH 7.4, 10% glycerol, 1 mM Cl
2
Ca, 1 mM Cl
2
Mg, 400 μM sodium vanadate, 0.2 
mM PMSF, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 0.1% phosphatase inhibitor cocktails I 
and II of Sigma-Aldrich). Blots were probed with rabbit polyclonal antibodies to Bim (H-
191) and HA (Y-11) from Santa Cruz Biotechnology (Dublin, Ireland). Phospho 
(Thr172) AMPKα antibody, total AMPKα, phospho (Thr183/Thr185) JNK, total JNK, 
phospho (Ser473) AKT, total AKT, phospho (Ser63) c-Jun, phospho (Ser2448) mTOR 
total mTOR, phospho (Ser253) FOXO3 and phospho (Thr32) FOXO3 all from Cell 
Signaling, and anti-Myc tag and total FOXO3 antibodies from Millipore (Carrigtwohill, 
Ireland). Blots were also probed with mouse monoclonal antibodies to β-actin (clone DM 
1A) and Anti-flag M2 from Sigma-Aldrich, and Neu-N and Anti-Phosphoserine clone 
4A4 from Millipore. Horseradish peroxidase conjugated secondary antibodies from 
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Thermo Scientific (Fisher, Dublin, Ireland) were detected using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific) and imaged using a FujiFilm LAS-3000 
imaging system (FujiFilm, Dublin, Ireland). To normalize for protein load, membranes 
were reblotted (Re-Blot, Millipore) and incubated with an appropriate control antibody. 
Levels of the protein under study were expressed relative to protein load in each lane as 
determined by appropriate control protein content. pAMPKα levels were normalized to β-
actin, as glutamate treatment decreased total AMPK levels. Densitometry analysis was 
performed using Image J software (NIH). A representative blot is shown from a total of at 
least three independent experiments, except where indicated. Immunoprecipitation was 
performed in cultured neurons lysed in PIK buffer and centrifuged at 22,000× g for 20 
min, and supernatants were incubated with antibodies bound to 25% agarose (Santa Cruz 
Biotechnology) overnight. The immunoprecipitates were washed three times with the 
same lysis buffer, resuspended in 2.5× SDS loading buffer and analyzed by Western blot. 
 
Cytosolic and nuclear fractionation. Nuclear and cytosolic fractions were obtained from 
total neuronal lysates as described
39
. The quality of the fractionation was determined by 
assaying for the presence of the nuclear protein Neu-N. 
 
Cell death assays. CGNs were cultured on 24-well plates. For determination of apoptotic 
morphology cells were stained live with Hoechst 33258 at a final concentration of 1 
μg/ml. After incubation for 10 min, nuclear morphology was observed and cells with 
condensed nuclei were scored as pyknotic and expressed as a percentage of the total 
population. For determination of neuronal mortality cells were transfected with a pMax-
 24 
GFP and different constructs under evaluation in a 1:5 ratio. GFP positive cells (GFP
+ 
cells) were counted prior to treatment to determine the baseline level of transfected cells 
at time point 0, and were counted again 24 h after treatment. Results were expressed as 
percentage of GFP
+ 
cells at time 0. Neurons were counted in twelve different fields using 
an Eclipse TE 300 inverted microscope (Nikon) and a 20x 0.45NA objective. All assays 
were done in triplicate in at least 3 independent experiments. 
 
Luciferase assays. CGNs were transfected with a luciferase reporter constructs containing 
different promoters along with a Renilla luciferase expression plasmid (pRL-TK) for 
normalization. Neurons were lysed in passive lysis buffer and luciferase activity was 
analyzed using a luminometer and dual luciferase assay kit according to the manufacturer 
Promega (Medical Supply, Dublin, Ireland). Transfections were performed in triplicate 
dishes and Luciferase counts (RLUs) were normalized using TK Renilla luciferase co-
transfection. Background luminescence was subtracted, and Luciferase activity was 
expressed as fold of the increase with respect to the control.  
 
Immunocytochemistry. Following treatment, CGNs cultured on glass coverslips were 
fixed (3% paraformaldehyde), permeabilised (0.1% Triton x-100 in PBS), blocked (5% 
horse serum (Invitrogen Bio Sciences, Dublin, Ireland), 0.3% Triton x-100 in PBS) and 
incubated with an antibody against FOXO3 (Millipore, Carrigtwohill, Ireland), at room 
temperature for 2 h. FOXO3 staining was detected with an anti-rabbit Alexa-Fluor-568-
conjugated secondary antibody (Invitrogen). Nuclei were also stained with Hoechst 
33258. CGNs were imaged on the LSM710 microscope detailed above and excited using 
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561 nm, 488 nm and 405 nm lasers. Images were analysed using ImageJ. The 
cytoplasmic and nuclear FOXO3 average intensity was quantified and CGNs were scored 
as cytoplasmic, nuclear or cyto/nuclear as described above. 
 
Gene targeted mice. The generation and genotyping of bim-/- mice has been previously 
described
40
. The bim-/- mice were originally generated on a mixed C57BL/6x129SV 
genetic background, using 129SV derived ES cells, but had been backcrossed for >12 
generations onto the C57BL/6 background. 
 
Oxygen and glucose deprivation in cortical neurons. Cortical neurons cultured on 24-
well plates were transfected with a pMax-GFP plasmid and different constructs under 
evaluation in a 1:5 ratio. Prior to OGD induction, cells were rinsed in pre-warmed 
glucose free media and transferred to the anaerobic chamber. The anaerobic chamber had 
an atmosphere consisting of 1.5% O2, 5% CO2 and 85% N2. Cells were incubated in 
OGD media consisting of 2 mM CaCl2, 125 mM NaCl, 25 mM NaHCO3, 2.5 mM KCl, 
1.25 mM NaH2P04, 2 mM MgSO4, and 10 mM Sucrose and had a pH of 7.4. After 30 
min of OGD, cells were returned to normoxic conditions containing 21% O2 and 5% 
CO2. Control cells remained in normoxic conditions throughout. 24 h later cells were 
stained live with Hoechst 33258 and cell death assessed as described above. 
 
Computational modeling. We modeled the AMPK-dependent FOXO3 activation by 
translating the reaction networks shown in Fig. 5A into Ordinary Differential Equations. 
As model input, different activation profiles of AMPK (pAMPK) were resembled by a 
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Gaussian curve with a maximum of 270 nM at a reference time point and full-width-half-
maxima between 0 to 150 min to mimic transient and prolonged activation. In a first 
activation step, phosphorylated AMPK (pAMPK) was assumed to inhibit mTOR and 
AKT activity, leading to dephosphorylation of FOXO3 (FOXO3dephos). In a second 
activation step (Fig. 5A (2)), pAMPK directly phosphorylated FOXO3dephos to a fraction 
(FOXO3AMPK) assumed to be capable of inducing bim transcription. The reaction network 
is depicted in Supplementary Table 1. Protein-protein interactions, including all 
phosphorylation and dephosphorylation events, were modeled by mass action kinetics, 
while a Hill kinetic was assumed for bim transcription. First order degradation kinetics 
were assumed for dephosphorylated proteins. Phosphorylated protein fractions were 
assumed to recover to steady state level. The complete Matlab code is available by 
request from the authors. 
 
Statistical analysis. Data are expressed as mean ± standard error. Differences among 
groups were analyzed by one-way ANOVA followed by Tukey test. Comparison between 
two groups was performed with the t test. p<0.05 was considered significant. 
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1. Bim induction during excitotoxic apoptosis requires AP-1 and FOXO3. (A) 
Western blot analysis showed a significant increase in Bim levels within a 4-24 h time 
frame after glutamate/glycine (100 µM /10µM, 30 min) exposure (*p<0.05; n=5). β-actin 
served as loading control. (B) CGNs from bim-/- mice and wild-type (wt) controls were 
treated with glutamate or experimental buffer (sham conditions). 24 h post treatment the 
neurons were stained live with Hoechst and pyknotic nuclei scored (*p<0.05; n=3). Bar, 
2.5 µm (C) CGNs were transfected with a vector containing a 0.8 kB fragment of the bim 
promoter. Bim promoter activation was significantly increased 24 h after glutamate 
exposure (*p<0.05; n=3). Mutations of the FOXO3 and AP-1 binding sites significantly 
reduced this activation (*p<0.05; n=3). 
 
Figure 2. Down-regulation of the mTOR / AKT pathway during excitotoxicity. (A)  
CGNs exposed to glutamate / glycine (100/10 µM, 30 min) increased phospho Thr172 
AMPK α levels 10-30 min after exposure (*p<0.05; n=3). β-actin served as loading 
control. (B) Glutamate exposure permanently decreased phospho Ser 2448 mTOR levels 
(*p<0.05; n=3). Total mTOR and β-actin served as loading controls. (C) Glutamate 
reduced phospho Ser 473 AKT levels 10 min-2 h after glutamate exposure (*p<0.05; 
n=4). Total AKT and β-actin served as loading controls. (D) Glutamate reduced phospho 
Thr 32 FOXO3 levels 2 h after glutamate exposure (*p<0.05; n=6). Total FOXO3 and β-
actin served as loading controls. (E) CGNs were transfected with AMPK siRNA or 
Control siRNA expressing vectors prior to glutamate exposure. Phospho Ser 473 AKT / 
Thr 32 FOXO3 levels were analyzed (1 h and 2 h) after glutamate exposure. AMPK 
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siRNA neurons presented higher levels than control siRNA neurons at both time points 
(*p<0.05; n=3). Total AKT, FOXO3 and β-actin served as loading controls. AMPK 
depletion was monitored by quantification of total AMPK α levels (Supplementary Fig. 
1). (F) CGNs were transfected with AKT-CA or a control construct prior to glutamate 
exposure. AKT-CA neurons presented significantly higher phospho (Thr32) FOXO3 
levels than control neurons (2 h and 4 h) after glutamate exposure (*p<0.05; n=3). Total 
FOXO3 and β-actin served as loading controls. AKT-CA expression was monitored by 
total AKT levels.  
 
Figure 3. AMPK activation during excitotoxicity induces FOXO3 nuclear 
translocation. (A-D) CGNs were transfected with a FOXO3-GFP construct. (A) Traces 
of the nuclear / cytoplasmic FOXO3-GFP ratio in single CGNs as monitored using time-
lapse microscopy. Following treatment with glutamate/ glycine (100/10 µM) for 30 min, 
29.3 ± 8.3% of the neurons showed an increase in the nuclear / cytoplasmic FOXO3-GFP 
ratio, and its persistence was associated with a drop in GFP signal and neuronal death as 
indicated by PI uptake. Representative traces are shown. (B) Images extracted from the 
time lapse series showing a CGN with FOXO3-GFP only in the cytoplasm at the start of 
the time series (1 h), persistent translocation of FOXO3-GFP to the nucleus (4.5 h), 
shrinkage of the nucleus (6.5 h), and subsequent secondary necrosis (12 h), bar: 10m. 
(C) FOXO3-GFP was co-expressed with the AKT-CA construct or a control vector. In 
the presence of the control vector, glutamate treatment increased the percentage of 
neurons with nuclear FOXO3-GFP (black bars) 3.5 h after exposure, and decreased the 
percentage with cytoplasmic FOXO3-GFP (white bars) (*p<0.05; n=3). AKT-CA 
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expression prevented both effects. (D) CGNs were pre-treated with CC (10 µM) or 
vehicle for 45 min prior to glutamate exposure. CC pre-treatment significantly reduced 
the increase in the percentage of cells with nuclear FOXO3-GFP (black bars), and the 
decrease in those with cytoplasmic FOXO3-GFP (white bars), 3.5 h after glutamate 
exposure (*p<0.05; n=3). (E) CGNs were exposed to glutamate 48 h after transfection 
with AMPK siRNA or Control siRNA and were fixed and stained 3.5 h later with 
Hoechst and an antibody against FOXO3. AMPK siRNA significantly reduced the 
glutamate-induced increase in nuclear FOXO3 (black bars) and decrease in cytoplasmic 
FOXO3 (white bars), confirming the effects seen in (D) (*p<0.05; n=4). (F) Images of 
single CGNs transfected with GFP-tagged siRNA and stained with an antibody against 
FOXO3 (red) and with Hoechst (blue), showing primarily nuclear (image series on left) 
or cytoplasmic (image series on right) FOXO3 staining. Bar = 5 µM. 
 
Figure 4. FOXO3 nuclear translocation is not sufficient for bim expression and cell 
death. (A) Traces of the FOXO3-GFP ratio in single CGNs exposed to glutamate and 2h 
later treated with Compound C (CC, 10 µM). In this case, all neurons which suffered a 
persistent FOXO3 nuclear translocation did not suffer subsequent nuclear shrinkage or 
cell death until termination of experiment. Representative traces are shown. (B) Images 
extracted from the time lapse series showing a CGN with FOXO3-GFP in the cytoplasm 
at the start of the time series (1 h), persistent translocation of FOXO3-GFP to the nucleus 
(6h), no shrinkage of the nucleus (12h), and no subsequent secondary necrosis (16 h), 
bar: 10 m. (C) Compound C (10 µM) addition 2 h after glutamate exposure significantly 
reduced the glutamate-induced increase in Bim expression (measured 8 h after glutamate 
 35 
exposure). β-actin served as loading control. (D) Compound C (10 µM) addition 2 h after 
glutamate exposure did not prevent the glutamate-induced decrease in cytoplasmic (cyto) 
FOXO3 or increase in nuclear FOXO3 levels (measured 8 h after glutamate exposure). β-
actin and Neu-N served as loading controls. (E) Addition of Compound C (10 µM) 2 h 
after glutamate treatment significantly reduced the % of PI
+
 cells detected 16 h after the 
excitotoxic insult. (F) CGNs exposed to continuous AICAR (2.5 mM) treatment showed 
an up-regulation of Bim levels in the cytosol, and pAMPK (Thr172) α and FOXO3 levels 
in the nucleus. CGNs exposed to transient AICAR treatment (2.5 mM, 1 h, then washout) 
also showed increased nuclear FOXO3 levels, however Bim levels in the cytosol and 
pAMPK in the nucleus were not up-regulated. β-actin and Neu-N served as loading 
controls. Times (h) indicate duration of AICAR treatment (continuous) or recovery times 
following washout of AICAR. 
 
Figure 5. FOXO3 activation by AMPK is a coherent feed-forward network motif 
that can act as a suppressor of transient stress signals. A second activation step of 
FOXO3 is necessary to explain neuronal tolerance to short-term pAMPK activity while 
maintaining Bim expression following prolonged pAMPK activity. (A) pAMPK-
mediated FOXO3 activation was initially modeled by a linear pathway (denoted by (1)). 
(B) This linear pathway predicted similar Bim expression patterns following short- and 
long-term periods of pAMPK activity and conflicted with recent findings of the 
neuroprotective role of pAMPK 
11
. (C) Incorporation of the second activation step 
(denoted by (2) in (A)) reduced Bim expression following short-term pAMPK activity 
(40 min, grey bars). This network structure represents a coherent feed-forward loop 
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(CFL) and, by preventing Bim expression in times of short-term stress, may allow 
pAMPK to exert its pro-survival effects. Significant Bim expression is still present 
following long-term pAMPK activity (100 min, black bars). Bars indicate relative 
differences in expression levels between both scenarios.  
 
Figure 6. AMPK induces bim expression by direct FOXO3 phosphorylation. (A) 
Upper. CGNs were co-transfected with a vector containing the bim promoter and either 
the wild type FOXO3 or FOXO3-6A constructs. Glutamate/Glycine (100/10 µM, 30 min) 
exposure significantly increased bim promoter activation in cells transfected with FOXO3 
wild type (*p<.05; n=4). FOXO3-6A expression prevented this effect (*p<0.05; n=4). (A) 
Lower. Western-blot analysis confirmed the effect of FOXO3-6A on Bim protein levels 
after glutamate exposure (30min). Results are representative of two independent 
experiments. (B) Upper. Nuclear fraction of CGNs transfected with FOXO3-Flag wt or 
FOXO3-6A-Flag constructs. Flag-tag detection by Western-blot and densitometry 
analysis showed a similar up-regulation of both constructs 4h after glutamate exposure 
(*p<0.05; n=4). Nuclear phospho (Thr172) AMPKα levels were also up-regulated. Neu-
N was used as nuclear marker and β-actin as loading control. (B) Lower. Glutamate 
exposure down-regulated levels of FOXO3 wt and FOXO3 6A. Cytoplasmic phospho 
(Thr172) AMPKα levels were also down-regulated. β-actin served as loading control. 
Representative blots are shown. (C) CGNs transfected with a ‘FOXO3-nuclear’ mutant 
(tagged with a flag-HA) and immunoprecipated showed an increase in Ser-
phosphorylation 4h after glutamate exposure (*p<0.05; n=3). Pre-treatment with CC (10 
µM) for 45 min. abrogated this effect (*p<0.05; n=3). (D) CGNs were co-transfected 
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with a luciferase reporter containing a MnSOD promoter sequence (pSOD-luc) and either 
wild type FOXO3 or FOXO3-6A. Glutamate exposure increased luciferase activity in 
cells transfected with FOXO3 wt. However, FOXO3-6A expression increased luciferase 
activity in neurons exposed to experimental buffer or glutamate. This effect was 
abrogated by mutation of the FOXO3 binding sites in the MnSOD promoter (pSOD-luc-
mut) (*p<0.05; n=4). 
 
Figure 7. FOXO3 activation by AMPK is required for cell death. (A) CGNs were co-
transfected with GFP and either the FOXO3 wt, dominant negative FOXO3 (DN-
FOXO3), or FOXO3-6A expression plasmid. FOXO3-wt transfected neurons treated with 
glutamate showed a significantly higher percentage of cell death (31.4 ± 3.8 % of total 
cells) than neurons exposed to vehicle (6.4 ± 2.7%) 16h after glutamate/glycine (100/10 
µM, 30 min) exposure. However, cell death after the excitotoxic insult was negligible in 
cells transfected with DN-FOXO3 or FOXO3-6A, which presented a significant decrease 
in the percentage of cell death compared to FOXO3-wt transfected neurons (*p<0.05; n 
=3). (B) Cortical neurons were co-transfected with a GFP-expression vector and
 
either 
AMPK siRNA, DN-FOXO3, or FOXO3-6A expression constructs. 72 h after transfection 
cultures were subjected to OGD (30 min) in a hypoxia chamber, and returned to 
normoxic/normoglycemic conditions. Cell death was determined 24 h later by evaluating 
the percentage of pyknotic nuclei in the GFP
+
 cells following Hoechst staining. 
Expression of either FOXO3-6A or DN-FOXO3 significantly reduced the percentage of 
neuronal cell death (13.0±7.8% and 12.0±7.8% of total cells, respectively) compare to 
cells co-transfected with a control plasmid (31.6 ± 4.6 %) (*p<0.05; n =4). Bar, 10 µM. 
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Supplementary Figure 1 CGNs transfected with AMPK siRNA had significantly 
depleted total AMPKα levels compared to CGNs transfected with control siRNA, both in 
sham conditions or after 1 and 2 hours of glutamate/glycine (100/10 µM, 30 min) 
exposure (*p<0.05; n=3 independent experiments). The excitotoxic insult also 
contributed significantly to the depletion of total AMPKα levels (Student’s t test for 
comparison between groups). Total AMPKα and -actin levels were quantified via 
Western Blot. AMPK levels were normalized relative to -actin levels and the resulting 
ratios were expressed as percentage of the control group (sham-treated CGNs with 
control siRNA vector).  
 
Supplementary Figure 2 (A) AMPK-CA expression increased c-JUN/ Bim levels 
compared with cells transfected with a control vector. Decreases in phosphor-mTOR (Ser 
2448), phosphor-AKT (Ser 473), and phospho-FOXO3 (Thr 32) levels were also 
detected. Total mTOR, AKT, FOXO3 and β-actin served as loading controls. AMPK-CA 
transfection was monitored by Myc-tag detection. Results are representative of at least 
two independent experiments. (B) CGNs were co-transfected with a bim promoter 
reporter construct and either AMPK-CA or a control vector. Expression of AMPK-CA 
significantly increased bim promoter activation (*p<0.05; n=3). This effect was 
abrogated by the mutation of either the FOXO3 or AP-1 binding sites at the bim promoter 
(*p<0.05; n=3). (C) FOXO3-GFP was co-expressed with the AMPK-CA construct or a 
vector control. AMPK-CA expression significantly increased the percentage of cells with 
nuclear FOXO3-GFP (black bars) with respect to control neurons (*p<0.05; n=3).  
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Supplementary Figure 3. (A-C) Traces of the nuclear / cytoplasmic FOXO3-GFP ratio 
in single CGNs as monitored using time-lapse microscopy. Representative traces are 
shown. (A, B) After treatment with glutamate/glycine (100/10 µM, 30 min), (A) 34.3 ± 
10.6% of the total cells did not show any significant variation in their nuclear / 
cytoplasmic FOXO3-GFP ratio, while (B) 28.5 ± 10.1% of the cells showed temporal 
increases in their FOXO3-GFP ratio. (C) Exposure of CGNs to sham conditions 
(experimental buffer) did not induce any significant variation in the FOXO3-GFP ratio.  
 
Supplementary Figure 4. (A) CGNs were co-transfected with a vector containing the 
bim promoter and either FOXO3 wild type or ‘FOXO3-nuclear’ (mutant permanently 
located in the nucleus). Glutamate/glycine (100/10 µM) exposure significantly increased 
bim promoter activation in cells transfected either with the FOXO3 wild type or with 
FOXO3 nuclear (*p<0.05; n=3). (B) CGNs were co-transfected with a luciferase reporter 
construct bearing six canonical FOXO binding elements (6xDBE-FOXO3) and either 
wild type FOXO3 or FOXO3-6A. Luminescence activity was normalized to the activity 
of the co-transfected RL-TK-luc and expressed as fold of increase with respect to the 
control. Glutamate/glycine (100/10 µM) exposure significantly increased luciferase 
activity in cells transfected either with wt FOXO3 or with FOXO3-6A (*p<0.05; n=4).  
 
Supplementary Table 1: A sketch of the ODE-based computational model incorporating 
the CFL: (Upper panel) Entities used in the model, their biological representative and 
their initial concentrations are given. (Lower panel) Pseudo-reaction system. Reaction 
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rates were assumed by using mass action kinetics (Eq. 2-5), first order protein 
degradation (Eq. 6-10), protein synthesis (Eq. 11-13) and a second order Hill kinetic (Eq. 
14) for bim transcription in the presence of the active FOXO3 form (FOXO3ampk). 
Phosphorylated AMPK (pAMPK) was modeled as input (Eq. 1) with Gaussian 
shape
2
2
2
)(
exp)(

 tAtpAMPK . Amplitude and maximum time of pAMKP activity 
was determined as A=270 nM, and μ=120 min. The full-width-half-maximum (FWHM = 
2.35σ) was varied from 0 to 150 min to mimic different durations of AMPK activation.  
 
AB
Bim promoter AP-1 site mutated
Bim promoter FOXO3 site mutated
Bim promoter Wild Type 
Glut / Gly (100/10 µM)
ytivitcar et r op er
esa r eficu
L
)e sae rcn i
d l oF (
*
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
- - - + + +
+ - - + - -
- + - - + -
- - + - - +
0
100
200
300
  β-Actin
Bim
*
O
pt
ic
al
 D
en
si
ty )lortnocfo
%(
Sham    10’      30’      2 h     4 h       8 h     16 h    24 h
Time after glutamate treatment 
Sham Glut
WT
bim -/-
Sham
ielcun
citonky
P
%
0
20
40
60
80
100 *
C
WT
bim -/-
/Gly
*
**
Figure 1
Glut /Gly
Figure 2 
0
50
100
150
200
A B
C
p-AKT(Ser473)
AKT
β-Actin
*
p-mTOR(Ser2448)
β-Actin
mTOR
β-Actin
*
p-FOXO3(Thr32)
FOXO3
AKT
β-Actin
)p-FOXO3(Thr32
FOXO3
β-Actin
Sham 10’ 30’ 2 h 4 h 8 h 16 h 24 h
Time after glutamate treatment 
0
50
100
150)lortnocfo
%(
p-AKT (Ser 473)
β-Actin
AKT
en
si
ty
Dlacitp
O
nt
ro
l)
ocfo
%(
E F
0
50
100
150
*
yt
sne
Dlacitp
O
)lortnocfo
%(
pAMPKα(Thr172)
AMPK siRNA
Control siRNA
AKT-CA
Control plasmid- - +- + +
--+ -++
- - +- + +
--+ -++
p-FOXO3a (Thr32)
FOXO3a
0
50
100
150
T
K
A-p
3
O
X
OF-p
Sham 2 4 Sham 2 4
Sham 1 2 Sham 1 2
D
0
50
100
150 * *
Time (h) after glutamate treatment
*
*
* *
0
50
100
150
200 * *
Sham 10’ 30’ 2 h 4 h 8 h 16 h 24 h
Sham 10’ 30’ 2 h 4 h 8 h 16 h 24 hSham 10’ 30’ 2 h 4 h 8 h 16 h 24 h
i
yt
sne
Dlacitp
O
i
)lortnocfo
%(
yt
sne
Dlacitp
O
i )lortnocfo
%(
yt
sne
Dlacitp
O
i
)lortnocfo
%(
yt
sne
Dlacitp
O
i
Time after glutamate treatment 
Time after glutamate treatment Time after glutamate treatment 
Time (h) after glutamate treatment
A


0
0.5
1
1.5
2
 1 2 3 4 5 6 7 8 9 10 11 12  13
FOXO3-GFP
PI
Hoechst 33258
1 4.5 6.5 12
Time (h) after glutamate treatment 
Glut/Gly
Compound C
- - + +
+-+-
D
*
*
F
noitubirtsid
PF
G- 3
O
X
O %(
noitalupopllecfo
)
0
20
40
60
80
100
C
Glut/Gly
Control plasmid
AKT-CA
+--
+ - + -
+
+-+-
*
*
0
20
40
60
80
100
F
noitubirtsid
PF
G-3
O
X
O %(
noitalupopllecfo
)
Nuclear
Cyto+Nuclear
Cytoplasmic
Nuclear
Cytoplasmic
B
N
uc
le
ar
 / 
C
yt
op
la
sm
ic
 F
O
X
O
3-
G
FP
 ra
tio
Figure 3
*
*
F
E
Cyto+Nuclear
Time (h) after glutamate treatment 
Hoechst 33258
GFP
α-FOXO3
Glut/Gly
Control siRNA
- - + +
-+-+
α-
FO
X
O
3 
di
st
rib
ut
io
n
%(
noitalupopllecfo
)
Nuclear
Cytoplasmic
Cyto+Nuclear
0
20
40
60
80
100
* *
* *
Nuclear 
FOXO3
Cytoplasmic 
FOXO3
AMPK siRNA - + - +
N
uc
le
ar
 / 
C
yt
op
la
sm
ic
 F
O
X
O
3-
G
FP
 ra
tio
0
0.5
1
1.5
2
   Compound C
   addition
A
1     6 12 16
Time (h) after glutamate treatment
FOXO3-GFP
PI
Hoechst 33258
B
C D
0
20
40
60
htaedlle
C
(
P
I
fo
%
)sllec+
+ +
- +
*
E
Figure 4
0
50
100
150
200
250
Sham     2 h      4 h       8 h 
Time after AICAR
(2.5 mM for 1 h)
    administration
Time after AICAR
(2.5 mM continuous)
      administration
FOXO3 (cyto)
FOXO3 (nuclear)
Neu-N (nuclear) 
α
* *F
Time (h) after glutamate treatment
* *
si
ty
ne
Dlacitp
O
)l ort nocfo
%(
Glut/Gly +-
- +
+
-Compound C
0
50
100
150
β-actin (cyto)
Bim (cyto)
Bim (cyto)
(2 h after Glut)
+-
- +
+
-
)lort nocfo
%(
FOXO3 (nuclear)
Glut/Gly
Compound C
(2 h after Glut)
Glut/Gly
Compound C
(2 h after Glut)
si
ty
ne
Dlacitp
O
B
im
 (c
yt
o)
FO
X
O
3 
(c
yt
o)
si
ty
ne
Dlacitp
O
)l ort nocfo
%(B
im
 (c
yt
o)
pAMPK (Thr172)   (cyto)
αpAMPK (Thr172)   (nuclear)
Sham     2 h      4 h       8 h 
1 2 3 4 5 6 7 8 9 10 11 12131415161718 19
β-actin (cyto)
FOXO3 (cyto)
β-actin (cyto)
*
*
0
150
100
50
Neu-N (nuclear)
12
 Model Incorporating Coherent Feed-Forward Loop (CFL)A
B
Two-step FOXO3 activation
0 10' 30' 2h 4h 8h 16h 24h
0
Short-term pAMPK activity (40 min)
Long-term pAMPK activity (100 min)
max.
)
U
A(
noitartnecno
C
mi
B
Simulation Time
0 10' 30' 2h 4h 8h 16h 24h
0
Short-term pAMPK activity (40 min)
Long-term pAMPK activity
 (100 min)
max.
)
U
A(
noitartnecno
C
mi
B
Simulation Time
C
pAMPK
mTOR
AKT
FOXO3aktFOXO3dephos
Bim
FOXO3ampk
‘Linear’ Pathway Model [     only]
Predicted Bim Expression
Model Incorporating CFL
       Predicted Bim Expression
1
 [     +     ]1 2
Figure 5
0100
200
300
B
β-actin
Flag M2-tag
p-AMPK(Thr 172)
AMPK
Neu-N
Flag M2-tag
Cytosolic fraction
C
* *
Nuclear fraction
p-AMPK(Thr 172)α
AMPKα
α
α
FOXO3 wild type
FOXO3 6A
- + +-
- -++
-- + +
D
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
FOXO3 wild type
FOXO3 6A
- +
++
--
ytivitcaretroper
esareficuL
(F
ol
d
in
)esaerc
pSOD-luc ++
pSOD-luc-mut --
- +
+ +
- -
++
--
- +
+ +
- -
++
--
* *
Figure 6
A
actin
0 .4
0 .6
0 .8
1
1.2
1.4
1.6
1.8
2
Bim
β-
Empty vector
FOXO3 wild type
FOXO3 6A
FOXO3 wild type
FOXO3 6A
ytivitcaretroper
esareficuL
(F
ol
d
in
)esaerc
*
- - - + + +
+ - - + - -
- + - - + -
- - + - - +
- + +-
- -++
-- + +
*
Glut /Gly
Glut /Gly
Glut /Gly
Glut /Gly
phospho-serine
Flag-HA-tag
FOXO3 nuclear
Compound C
- + +
++
-- +
+
0
50
100
150
200
250
300
Glut /Gly
si
ty
ne
Dlacitp
O
)lortnocfo
%(
si
ty
ne
Dlacitp
O
)lortnocfo
%(
* *
010
20
30
40
50
60
FOXO3 wild type
FOXO3 6A
A
htaedlle
C
B
GFP
OGD /
AMPK siRNA
OGD /
Control plasmid
OGD /
FOXO3 6A
OGD /
DN-FOXO3
Signal
OGD
Control plasmid
AMPK siRNA
DN-FOXO3
FOXO3 6A
* *
0
10
20
30
40
%
P
yk
no
tic
 N
uc
le
i
- + +-
- -++
-- + +
+ + + +
+ - - -
- + - -
- - + -
- - - +
DN-FOXO3 -- - -
+-
- -
+ +
- -
* **
Figure 7
(%
 o
f d
ea
d 
G
FP
  c
el
ls
)
+
Glut /Gly
Supplementary figure 1
0
20
40
60
80
100
120
*
*
AMPK siRNA
Control siRNA
- - +- + +
--+ -++
Time (h) post Glut (100µM)
/ Gly (10µM) addition
Sham 1 2 Sham 1 2
β-Actin
AMPKα
* *
ns
ity
 ra
tio
ed lacitp
O
nt
ro
l)
oc fo 
%(  A
M
P
K
α
 / 
β-A
cti
n
Ap-FOXO3(Thr32)
p-mTOR(Ser 2448)
Bim
β-Actin
mTOR
FOXO3
AMPK-CA
p-Akt (Ser 473)
Akt
AMPK-CA
Control construct
Bim promoter AP1 site mutated
Bim promoter FOXO3 site mutated
Bim promoter Wild Type 
AMPK-CA
Control construct
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8 *ytivitcaretr op er
esar eficuL
) esaer cni
d l oF(
- +
-+ + - - + - -
- + - - + -
- - + - - +
- - - + + +
---+++
c-JUN
B
* *
C
Cytoplasmic
Nuclear
Cyto + Nuclear
n
*
F
oitubirtsid
PF
G-3
OX
O %(
noitalupopllecfo
)
Control plasmid
AMPK-CA
80
60
40
20
0
100
+ -
+-
Supplementary Figure 2
ATime (h) after glutamate treatment
1 2 3 4 5 6 7 8 9 10 11
N
uc
le
ar
/C
yt
op
la
sm
ic
 F
O
X
O
3-
G
FP
 ra
tio
B
C
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
0
0.5
1
1.5
2
0
0.5
1
1.5
2
0
0.5
1
1.5
2
Supplementary Figure 3
Time (h) after glutamate treatment
Time (h) after glutamate treatment
N
uc
le
ar
/C
yt
op
la
sm
ic
 F
O
X
O
3-
G
FP
 ra
tio
N
uc
le
ar
/C
yt
op
la
sm
ic
 F
O
X
O
3-
G
FP
 ra
tio
01
2
3
4
5
ytivitcaretroper
esareficuL
(F
ol
d
in
)esaerc
*
*
Glut/Gly
FOXO3 wild type
FOXO3 nuclear
- + +-
- -++
-- + +
0.4
0.6
0.8
1
1.2
1.4
1.6
ytivitcaretroper
esareficuL
(F
ol
d
in
)esaerc
* *
Glut/Gly
6xDBE FOXO3 promoter
FOXO3 wild type
FOXO3 6A
- + +-
- -++
-- + +
+ + ++
A
B
Supplementary Figure 4
Supplementary table 1 
 
 
  
  
 
Eq. Pseudo-Reaction System Reaction Rates 
1 AMPK (not modeled) → pAMPK Input 
 pAMPK + mTOR → pAMPK+imTOR 1.73 x 10-4 * pAMPK * mTOR 
3 imTOR+pAKT → imTOR+AKT 3.63 x 10-5 * imTOR * pAKT 
4 FOXO3akt + AKT → FOXO3dephos + AKT 4.39 x 10
-5 
* FOXO3akt * AKT 
5 pAMPK + FOXO3dephos → pAMPK +FOXO3AMPK 1.76 x 10
-6
 * pAMPK * FOXO3dephos 
6 AKT → 0 9.31 x 10
-2 
* AKT 
7 imTOR → 0 3.00 x 10-4 * imTOR 
8 FOXO3dephos → 0 3.00 x 10
-2
 * FOXO3dephos 
9 FOXO3ampk → 0 8.44 x 10
-3
 * FOXO3ampk 
10 Bim → 0 2.00 x 10-4 * Bim 
11 0 → mTOR 1.50 x 10-2 
12 0 → pAKT 2.82 x 10-3 
13 0 → FOXO3akt 3.63 x 10
-3
 
14 FOXO3AMPK → FOXO3ampk + Bim FOXO3AMPK 
2
/(FOXO3AMPK
2
+7) 
Entity Description Initial Concentration 
pAMPK  Phosphorylated (active) AMPK Input 
mTOR Mammalian Target of Rapamycin 50 nM 
imTOR Inhibited mTOR 0 nM 
pAKT  Phosphorylated AKT 9.4 nM 
AKT Dephosphorylated AKT 0 nM 
FOXO3akt AKT-phosphorylated FOXO3 24.2 nM 
FOXO3dephos Dephosphorylated FOXO3 0 nM 
FOXO3ampk AMPK-phosphorylated FOXO3 0 nM 
Bim  Bim protein 0 nM 
